Price-sensitive press releases
2025-06-16
Moberg Pharma AB (OMX: MOB) announces that Terclara[®], the company's innovative drug for treatment of nail fungus, is now the market leader also in Norway. This means that Terclara[®] is now the leading product in both Sweden and Norway, a testament to the product's strong impact among both pharmacies and consumers.
2025-06-03
Moberg Pharma AB (publ) today announces that the board of directors exercises authorizations to issue and repurchase class C shares, and converts class C shares to common shares, to secure the company’s commitments under incentive programmes and for the purpose of covering certain costs that may arise as a result of incentive programs.
2025-05-22
STOCKHOLM, May 22[th], 2025. Moberg Pharma AB (publ)’s (“Moberg Pharma” or the “Company”) Annual General Meeting took place today. The Annual General Meeting resolved in accordance with the Nomination Committee’s and Board of Directors’ proposals as set out below.
2025-05-13
TERCLARA NOW ALSO AVAILABLE IN NORWAY
2025-04-22
Shareholders in Moberg Pharma AB (publ), reg. no. 556697-7426, (the “Company”) are hereby convened to the Annual General Meeting on 22 May 2025 at 16:30 at Advokatfirman Schjødt, Hamngatan 27 in Stockholm.
2025-04-11
Moberg Pharma´s Annual report for 2024 has been published and is available on www.mobergpharma.com (https://www.mobergpharma.com/investors/annual-reports)
2025-02-11
TERCLARA CONTINUES TO LEAD THE MARKET AND EXPANDS TO NORWAY